A Cohort Establishment Study of Total Management of Ovarian Cancer
Study Details
Study Description
Brief Summary
A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
-
To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer);
-
To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures;
-
The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed;
-
To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
Study Design
Outcome Measures
Primary Outcome Measures
- Progress Freesurvival (PFS) [Average six months after study completion.]
The time from the start of treatment until the patient progresses further or dies.
- Overall Survival (OS) [Average six months after study completion.]
Measure the time from the start of treatment to the time of death.
Secondary Outcome Measures
- Occurrence of adverse reactions [Average six months after study completion.]
All adverse events were recorded.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;
-
Can cooperate with later follow-up.
Exclusion Criteria:
-
Patients with other malignant tumors or previous history of other malignant tumors;
-
Have cognitive impairment.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sichuan Cancer Hospital and Research Institute
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LCATM202304